BioLargo Net Income vs. Cash And Equivalents

BLGO Stock  USD 0.19  0.01  5.00%   
Considering BioLargo's profitability and operating efficiency indicators, BioLargo may not be well positioned to generate adequate gross income at the moment. It has a very high risk of underperforming in January. Profitability indicators assess BioLargo's ability to earn profits and add value for shareholders.
For BioLargo profitability analysis, we use financial ratios and fundamental drivers that measure the ability of BioLargo to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well BioLargo utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between BioLargo's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of BioLargo over time as well as its relative position and ranking within its peers.
  
Check out Trending Equities.
Please note, there is a significant difference between BioLargo's value and its price as these two are different measures arrived at by different means. Investors typically determine if BioLargo is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, BioLargo's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

BioLargo Cash And Equivalents vs. Net Income Fundamental Analysis

Comparative valuation techniques use various fundamental indicators to help in determining BioLargo's current stock value. Our valuation model uses many indicators to compare BioLargo value to that of its competitors to determine the firm's financial worth.
BioLargo is number one stock in net income category among its peers. It also is number one stock in cash and equivalents category among its peers . Comparative valuation analysis is a catch-all model that can be used if you cannot value BioLargo by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for BioLargo's OTC Stock. Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued.

BioLargo Cash And Equivalents vs. Net Income

Net income is the profit of a company for the reporting period, which is derived after taking revenues and gains and subtracting all expenses and losses. Net income is one of the most-watched numbers by money managers as well as individual investors.

BioLargo

Net Income

 = 

(Rev + Gain)

-

(Exp + Loss)

 = 
(7.08 M)
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
Cash or Cash Equivalents are the most liquid of all assets found on the company's balance sheet. It is used in calculating many of the firm's liquidity ratios and is a good indicator of the overall financial health of a company. Companies with a lot of cash are usually attractive takeover targets. Cash Equivalents are balance sheet items that are typically reported using currency printed on notes.

BioLargo

Cash

 = 

Bank Deposits

+

Liquidities

 = 
1.23 M
Cash equivalents represent current assets that are easily convertible to cash such as short term bonds, savings account, money market funds, or certificate of deposits (CDs). One of the important consideration companies make when classifying assets as cash equivalent is that investments they report on their balance sheets under current assets should have almost no risk of change in value over the next few months (usually three months).

BioLargo Cash And Equivalents Comparison

BioLargo is currently under evaluation in cash and equivalents category among its peers.

BioLargo Profitability Projections

The most important aspect of a successful company is its ability to generate a profit. For investors in BioLargo, profitability is also one of the essential criteria for including it into their portfolios because, without profit, BioLargo will eventually generate negative long term returns. The profitability progress is the general direction of BioLargo's change in net profit over the period of time. It can combine multiple indicators of BioLargo, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
BioLargo, Inc. invents, develops, and commercializes various platform technologies. BioLargo, Inc. was incorporated in 1991 and is based in Westminster, California. Biolargo operates under Chemicals classification in the United States and is traded on OTC Exchange. It employs 31 people.

BioLargo Profitability Driver Comparison

Profitability drivers are factors that can directly affect your investment outlook on BioLargo. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of BioLargo position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the BioLargo's important profitability drivers and their relationship over time.

Use BioLargo in pair-trading

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if BioLargo position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in BioLargo will appreciate offsetting losses from the drop in the long position's value.

BioLargo Pair Trading

BioLargo Pair Trading Analysis

The ability to find closely correlated positions to BioLargo could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace BioLargo when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back BioLargo - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling BioLargo to buy it.
The correlation of BioLargo is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as BioLargo moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if BioLargo moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for BioLargo can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching

Use Investing Themes to Complement your BioLargo position

In addition to having BioLargo in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.

Did You Try This Idea?

Run Most Shorted Equities Thematic Idea Now

Most Shorted Equities
Most Shorted Equities Theme
Dynamically calculated list of top equities currently trending upward via a buy-out by investors. The Most Shorted Equities theme has 217 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Most Shorted Equities Theme or any other thematic opportunities.
View All  Next Launch

Other Information on Investing in BioLargo OTC Stock

To fully project BioLargo's future profitability, investors should examine all historical financial statements. These statements provide investors with a comprehensive snapshot of the financial position of BioLargo at a specified time, usually calculated after every quarter, six months, or one year. Three primary documents fall into the category of financial statements. These documents include BioLargo's income statement, its balance sheet, and the statement of cash flows.
Potential BioLargo investors and stakeholders can use historical trends found within financial statements to determine how well the company is positioned for the future. Although BioLargo investors may work on each financial statement separately, they are all related. The changes in BioLargo's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on BioLargo's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet but not equivalent to net income shown on the income statement. Please read more on our technical analysis and fundamental analysis pages.